[Disclosure] Celltrion (068270) Submits Extension Application for Subcutaneous Formulation of Breast Cancer Treatment ‘Herzuma’ (CT-P6 SC) to European Regulatory Authorities

Source: Financial Supervisory Service Data Analysis, Retrieval and Transfer System (DART) / 2026-04-30

Disclosure Type: Major Business Matters Related to Investment Decisions

💡 3-Second Summary

On April 30, 2026, Celltrion officially submitted an extension application to the European Medicines Agency (EMA) and the European Commission (EC) for the subcutaneous (SC) formulation of its breast cancer treatment Herzuma (CT-P6 SC), following the successful completion of a Phase 1 clinical trial demonstrating pharmacokinetic equivalence to the reference product.

📊 1. [Key Disclosure Details & Major Figures Summary]

• Product Name & Indications: CT-P6 SC (Herzuma Subcutaneous Formulation) / Early breast cancer and Metastatic breast cancer
• Application Details:
  • Submission Date: April 30, 2026 (Local time)
  • Regulatory Bodies: European Medicines Agency (EMA) / European Commission (EC)
• Phase 1 Clinical Trial Summary & Results (Identifier: NCT06687928):
  • Subjects: 203 healthy male volunteers aged 19 to 55 years
  • Comparison Target: Herceptin subcutaneous formulation
  • Pharmacokinetic (PK) Results: The 90% confidence intervals for the primary endpoints, $AUC_{0-inf}$ and $C_{max}$, fell entirely within the pre-defined equivalence margin of $80\% \text{ to } 125\%$, successfully demonstrating pharmacokinetic equivalence between CT-P6 SC and reference SC groups.
  • Safety: Treatment-emergent adverse events (TEAEs) were reported in 89.5% of subjects, with comparable proportions between the two groups. Most events were mild or moderate, and no treatment-emergent serious adverse events (TESAEs) occurred.
  • Immunogenicity: The incidence of anti-drug antibodies (ADA) and neutralizing antibodies (NAb) against trastuzumab and rHuPH20 was low and comparable between the two groups, with no clinically meaningful safety impacts observed.
• Future Plans: Following this European extension application based on secured clinical data, Celltrion plans to sequentially submit applications to regulatory agencies in other countries.

📈 2. [Expert Perspective: What This Means for Investors]

• Strategic Initiative to Expand Market Footprint: This disclosure marks the formal administrative initiation to add a subcutaneous (SC) delivery option to Celltrion’s existing intravenous (IV) Herzuma product line in the European market. Offering an SC alternative represents a strategic attempt to enhance market competitiveness by catering to diverse clinical settings and patient needs.
• Validation via Quantitative Phase 1 Clinical Metrics: The submitted Phase 1 clinical data objectively met the strict regulatory bioequivalence criteria, showing pharmacokinetic parameters ($AUC_{0-inf}$, $C_{max}$) within the established $80\% \text{ to } 125\%$ boundary with no critical safety issues. Securing this statistical alignment was a prerequisite for submitting this official regulatory application.
• Inherent Regulatory Approval Risks: An application filing does not guarantee final regulatory approval. The review process by the EMA/EC may entail requests for additional data, potentially leading to adjustments or delays in the commercialization timeline. Investors should assess this development as a milestone in progress and continue to monitor the subsequent official approval decisions.

📝 Editor’s Comment (by K-STOCK Editor)

This announcement confirms that Celltrion has finalized its submission of the extension application for Herzuma SC (CT-P6 SC) in Europe. While the Phase 1 trial successfully delivered the required pharmacokinetic equivalence and comparable safety profiles to clear the filing threshold, the ultimate commercial launch hinges entirely on the final regulatory authorization from the EMA/EC. Rather than making premature assumptions about market release or financial impact, investors should maintain a objective view, tracking the regulatory progress and waiting for the official marketing authorization announcement.

📢 Disclaimer & Sources

Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.